Non-Hodgkin Lymphoma

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

Clémentine Sarkozy, MD, PhD, and Carla Casulo, MD, detail the evolution of lymphoma management strategies.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Panelists discuss how stem cell transplantation is considered primarily for younger patients or aggressive CTCL variants, balancing timing, remission status, and potential risks, while also emphasizing the value of early referral and specialized guidance for advanced disease.

Panelists discuss how decisions about reintroducing previous therapies for CTCL are based on prior tolerance, current disease state, and the reason for stopping treatment, with flexibility to recycle effective agents when appropriate.

Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.

Panelists discuss how to differentiate Mogamulizumab-associated rash from CTCL using clinical clues, biopsy findings, and molecular studies, and how treatment may be modified based on rash severity and characteristics.

Panelists discuss how to sequence and personalize therapy for Sézary syndrome, with mogamulizumab often used as first-line treatment due to potential for durable remission, followed by HDAC inhibitors, photopheresis, or alemtuzumab depending on disease progression and transplant planning.

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Panelists discuss how to integrate skin-directed therapies with systemic treatments for CTCL, emphasizing individualized strategies based on disease compartment, cautious layering of treatments, management of bacterial colonization (especially Staphylococcus aureus), and use of adjunctive measures, such as bleach baths, for optimizing skin health.

Panelists discuss how to manage advanced-stage mycosis fungoides with nodal or visceral involvement by adapting treatments typically used for peripheral T-cell lymphoma, including single-agent chemotherapy and HDAC inhibitors, while accounting for long-term toxicities and unique dose considerations due to patient fragility and tumor biology.

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

Panelists discuss how individualized treatment plans must consider disease location, drug access, comorbidities, and newer therapies—such as HDAC inhibitors and immune checkpoint inhibitors— while emphasizing the importance of managing expectations and monitoring adverse effects.

Panelists discuss how treatment goals and selection for advanced-stage cutaneous T-cell lymphoma depend on disease compartmentalization, with therapies like brentuximab vedotin and mogamulizumab being used based on specific disease characteristics and toxicity profiles.

Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.